ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma

Blood

Volumn 102, Issue 7, 2003, Pages 2638-2641

  De Paepe, Pascale ^b   Baens, Mathijs ^b   Van Krieken, Han ^b   Verhasselt, Bruno ^b   Stul, Michel ^b   Simons, Annet ^b   Poppe, Bruce ^b   Laureys, Geneviève ^b   Brons, Paul ^b   Vandenberghe, Peter ^b   Speleman, Frank ^b   Praet, Marleen ^b   De Wolf Peeters, Chris ^b   Marynen, Peter ^b   Wlodarska, Iwona ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE RECEPTOR; CD20 ANTIGEN; SYNDECAN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME 17P; CHROMOSOME 2P; CLTC ALK GENE; ENZYME ACTIVATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LARGE B CELL LYMPHOMA; MALE; MYOFIBROBLAST; NULL CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 0141705307     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1050     Document Type: Article

References (23)

1. Falini B, Pufford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94:3509-3515.
2. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
3. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623-5637.
4. Morris SW, Xue L, Ma Z, Kinney MC. Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. Br J Haematol. 2001;113:275-295.
5. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2002;34:354-362.
6. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood. 1997;89:1483-1490.
7. Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol. 1992;45:770-775.
8. Theodorou I, Delfau-Larue MH, Bigorgne C, et al. Cutaneous T-cell infiltrates: analysis of T-cell receptor gamma gene rearrangement by polymerase chain reaction and denaturing gradient gel electrophoresis. Blood. 1995;86:305-310.
9. Dierlamm J, Wlodarska I, Michaux L, et al. Successful use of the same slide for consecutive fluorescence in situ hybridization experiments. Genes Chromdsomes Cancer. 1996;16:261-264.
10. Mathew P, Sanger WG, Weisenburger DD, et al. Detection of the t(2:5)(p23:q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization. Blood. 1997:89:1678-1685.
11. Martin-Subero JI, Chudoba I, Harder L, et al. Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol. 2002;161:413-420.
12. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 1997;89:1394-1404.
13. ISCN. An International System for Human Genetic Nomenclature. Mitelman F, ed. Basel, Switzerland: Karger; 1995.
14. Downing JR, Shurtleff SA, Zielenska M, et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood. 1995;85:3416-3422.
15. Arber DA, Sun LH, Weiss LM. Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma. Hum Pathol. 1996;27:590-594.
16. Weisenburger DD, Gordon BG, Vose JM, et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. Blood. 1996;87:3860-3868.
17. Hutchison RE, Banki K, Shuster JJ, et al. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol. 1997;8(suppl 1):37-42.
18. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913-3921.
19. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood. 2000;95:3204-3207.
20. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrid heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol. 2001;159:411-415.
21. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 1997;90:2901-2910.
22. Lange K, Uckert W, Blankenstein T, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene. 2003;22:517-527.
23. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101:1919-1927.